ストックスクリーナーアプリを入手
9.34
0.86%
0.08
アフターアワーズ：
9.35
0.010
+0.11%
前日終値:
$9.26
開ける：
$9.39
24時間の取引高:
2.70M
Relative Volume:
0.54
時価総額：
$1.52B
収益：
$1.12B
当期純損益:
$440.30M
株価収益率:
3.9235
EPS:
2.3805
ネットキャッシュフロー:
$-251.02M
1週間 パフォーマンス:
-6.69%
1か月 パフォーマンス:
-1.99%
6か月 パフォーマンス:
+11.99%
1年 パフォーマンス:
+23.54%
1日の値動き範囲:
$9.22
$9.60
1週間の範囲:
$9.22
$10.00
52週間の値動き範囲:
$5.01
$11.97
Novavax Inc Stock (NVAX) Company Profile
Compare NVAX vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
9.34 | 1.51B | 1.12B | 440.30M | -251.02M | 2.3805 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-08-28 | 再開されました | H.C. Wainwright | Buy |
| 2025-08-20 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2025-06-17 | 開始されました | Citigroup | Sell |
| 2025-02-28 | 開始されました | BTIG Research | Buy |
| 2024-07-30 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-05-10 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-05-10 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-08-09 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | 繰り返されました | B. Riley Securities | Buy |
| 2022-12-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-12-02 | 開始されました | Jefferies | Hold |
| 2022-09-22 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-05-20 | 開始されました | BofA Securities | Underperform |
| 2022-02-23 | 繰り返されました | B. Riley Securities | Buy |
| 2022-02-22 | 再開されました | Jefferies | Buy |
| 2022-01-21 | 開始されました | Cowen | Outperform |
| 2021-05-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-14 | 開始されました | Jefferies | Buy |
| 2020-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-05 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-08-05 | ダウングレード | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | 繰り返されました | B. Riley FBR | Buy |
| 2020-06-29 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-05-28 | 繰り返されました | B. Riley FBR | Buy |
| 2020-05-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-27 | 再開されました | B. Riley FBR | Buy |
| 2019-08-14 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-28 | ダウングレード | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-12-11 | 開始されました | Oppenheimer | Outperform |
| 2018-11-26 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | アップグレード | JP Morgan | Underweight → Overweight |
| 2018-03-29 | アップグレード | Seaport Global Securities | Neutral → Buy |
すべてを表示
Novavax Inc (NVAX) 最新ニュース
Novavax Inc stock faces renewed scrutiny amid biotech sector volatility and pipeline updates - AD HOC NEWS
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
NVAX SEC FilingsNovavax Inc 10-K, 10-Q, 8-K Forms - Stock Titan
(NVAX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Novavax Inc. stock rises Monday, still underperforms market - MarketWatch
Novavax Q2 2025 Earnings Preview - MSN
Wall Street Recap: Can Novavax Inc stock outperform in a bear marketTrade Entry Report & AI Driven Stock Price Forecasts - baoquankhu1.vn
NVAX Technical Analysis | Trend, Signals & Chart Patterns | NOVAVAX INC (NASDAQ:NVAX) - ChartMill
Novavax Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Novavax Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Q3 Earnings Estimate for Novavax Issued By Zacks Research - MarketBeat
2 Healthcare Stocks to Target This Week and 1 That Underwhelm - The Globe and Mail
Assessing Novavax (NVAX) Valuation As Licensing Income And COVID Momentum Shape Expectations - Yahoo Finance
Aug Selloffs: Is Novavax Inc benefiting from interest rate changesMarket Growth Report & Entry and Exit Point Strategies - baoquankhu1.vn
NVAX stock rises overnight ahead of Q4 print with Pfizer tailwinds — analyst warns of 20% crash - MSN
Novavax (NVAX) Shares Drop 1.23%: Key Information to Note - Bitget
Novavax (NVAX) Stock Moves -1.23%: What You Should Know - Yahoo! Finance Canada
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Therapeutics Sector Q4 Results: Revenue Beats Amid Market Stability - IndexBox
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of "Hold" by Brokerages - MarketBeat
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Is trending stock Novavax, Inc. (NVAX) a buy now? - MSN
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax (NASDAQ:NVAX) Trading 7.6% HigherShould You Buy? - MarketBeat
Here’s What You Should Understand Besides the Reason Novavax, Inc. (NVAX) is Gaining Attention - Bitget
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock - Yahoo Finance
DC InnoNovavax cancels Covid-19 vaccine contract | Oxiwear is going global - The Business Journals
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Farallon Capital Management LLC Purchases 764,000 Shares of Novavax, Inc. $NVAX - MarketBeat
Nuvaxovid (Novavax) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F - Yahoo Finance
How (NVAX) Movements Inform Risk Allocation Models - Stock Traders Daily
FDA to Mandate Placebo-Controlled Trials for New Vaccines - MSN
Jefferies Maintains Buy on Novavax, Inc. (NVAX) March 2026 - Meyka
BTIG Maintains a Buy Rating on Novavax (NVAX), Sets a $19 PT - MSN
Novavax (NVAX) director John W. Shiver converts 7,947 RSUs into stock - Stock Titan
Jefferies reiterates Buy on Novavax stock, cites adjuvant platform By Investing.com - Investing.com India
Jefferies reiterates Buy on Novavax stock, cites adjuvant platform - Investing.com
Assessing Novavax (NVAX) Valuation After Strong 2025 Results And Return To Profitability - simplywall.st
Novavax (NASDAQ:NVAX) Share Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Novavax Q4 earnings preview: Wall Street expects wider losses amid diversification efforts - MSN
Novavax (NVAX) Gains Momentum with Sanofi Deal and Analyst Endorsement - MSN
Novavax stock hits over 1-year high: Is Sanofi’s flu-COVID shot the post-pandemic growth driver? - MSN
The 7 Most Hated Stocks on Wall Street Today | Investing - Money/ US News
NVAX: Pivot to platform partnerships and innovation drives growth, with profitability targeted by 2028 - TradingView
Novavax (NVAX) EVP granted 139,500 non-statutory stock options - Stock Titan
Novavax Inc. (NVAX) legal chief updates 152,000-share stock option terms - Stock Titan
Novavax (NVAX) EVP granted 177,500 options with revised terms - Stock Titan
Therapeutics Companies Exceed Q4 2025 Revenue Estimates, Led by Novavax and AmgenNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Novavax (NVAX) CEO updates exercise price on 551,500 stock options - Stock Titan
Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling - MSN
Novavax Inc (NVAX) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):